TIGIT competes with the activating receptor DNAM-1 for the ligands CD155 and CD112; thus, blocking TIGIT prevents the exhaustion of cancer-infiltrating NK cells and stimulates potent anti-cancer efficacy. Here, CD226 is linked to cancer.